Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.
about
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancerMatuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for DimerizationNovel advances in pancreatic cancer treatmentTargeted therapies for pancreatic cancer.Biological approaches to therapy of pancreatic cancer.Exploiting novel molecular targets in gastrointestinal cancers.Smarter drugs emerging in pancreatic cancer therapy.Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope.A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsPancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapyPancreatic Cancer: Progress in Systemic Therapy.High vascular delivery of EGF, but low receptor binding rate is observed in AsPC-1 tumors as compared to normal pancreas.Epidermal growth factor receptor as a major anticancer drug target.What is recent in pancreatic cancer immunotherapy?HER family inhibitors in pancreatic cancer: current status and future directions.Targeting signal transduction in pancreatic cancer treatment.Novel antibodies as anticancer agents.Her signaling in pancreatic cancer.Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check.Molecular targeted therapies for pancreatic cancer.Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000).Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumorsCombination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.Monoclonal antibodies in the treatment of pancreatic cancer.Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.Novel agents for the treatment of adenocarcinoma of the pancreas.Monoclonal antibody-induced cytokine-release syndrome.Current status of experimental therapeutics for head and neck cancer.Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.Immunotherapy for pancreatic cancer.Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.Emerging antibodies for the treatment of pancreatic cancer.A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration.Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2.Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF.Advanced pancreatic cancer: The standard of care and new opportunities
P2860
Q24649684-70D20742-F281-4A97-A3DB-BF41D737E901Q27650259-5228F631-09F2-45EC-BEA6-8300F9CABAB7Q28282794-292388B1-9A35-4C3D-A1CD-FF68ED9BD86DQ33899923-8DBA588D-335F-4656-A4EB-F7BD3A615EC8Q33899938-30446F73-B119-42F4-932E-75FB3C2A1E0DQ34382777-90BB04C8-1481-4F16-98E7-77A3E08DBD4AQ34410212-7C1092A6-5BE0-4EE5-A5E4-12F291CF3DFEQ34586272-ADC8B366-D157-4598-B590-3E2AB5809A45Q35214496-23F88670-1D0A-41EC-B21F-81812FA9BBB7Q35652789-8C76FCDB-FDBD-490F-9B9C-CB85D391F6F1Q35886496-D74116F1-DF38-4F2C-967D-9554AC0C9329Q36344551-D05C390C-7F29-449B-B934-0795C544A0BAQ36485041-D4079583-44B2-4937-98DE-C9C8AE78EC35Q36653667-A2CF0E33-F07C-484B-89A5-502AC9B376D5Q36665335-260534F6-6C46-4D0B-947C-1713E36CEA51Q36734936-47372B58-5761-4CFF-A4C1-B42E3258ABEEQ36804444-EB7DA655-03CB-49D1-9CB0-08BD5C0DEA2BQ36832141-47588503-F2BC-4374-97F8-19F95A7B8FE5Q36842715-21D8212A-5E7A-487D-8B9E-D803BEC4FF66Q36927353-34B44604-3A7B-4262-B481-9E1B2F7FB372Q36944441-43341B4C-2EA0-439D-837D-A6A95E9734C7Q37052752-49F591FF-1F58-41CF-95FC-189447B3B665Q37055023-01449819-9F6D-42BE-B0CD-B7E7FBF65EF6Q37299843-6301B54D-EBCF-48D2-A5EB-F499F942ABCFQ37355568-382FE21C-2454-4406-92EB-15413FD3C684Q37372980-3525B637-CC4B-4BBA-9B28-21ED4484EF32Q37614590-98F16919-420C-4D24-88B4-54FD9BD3E210Q37755276-4DCCE488-603D-4EF6-80A8-C0E7BFABC9FAQ37856044-7E87AE35-E2A8-4D66-961D-CF47983629ECQ38053855-4C356383-40E6-4747-BACB-B040340EC0D3Q38722325-26C4C92B-9F23-44DF-A4D0-89801AC5EED7Q39093873-C59E3355-FB65-4ACA-A68C-5943AEF3C453Q39158427-4A814B3D-8EA2-4772-BA62-111A3A73720AQ39885205-B1E4BCAF-6BFE-4634-824E-28ACC50F5858Q40141648-52AB1DB4-0515-4768-ACDC-2D244A05C0B1Q42661688-D64FA8ED-24AF-4ECE-BA6E-4DD9FA83695BQ43141124-CB8EE565-8C5A-4D73-AA3C-D6A1232EC1C4Q54494748-97C9E5D4-74D9-4CAD-AE9F-8F56A980784CQ54786239-E2E38716-45BB-4440-AD5F-FD49E6A4EC87Q57822243-408ADDE9-33C3-4647-A50C-19B686861BAC
P2860
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Phase I study of the humanised ...... in advanced pancreatic cancer.
@ast
Phase I study of the humanised ...... in advanced pancreatic cancer.
@en
type
label
Phase I study of the humanised ...... in advanced pancreatic cancer.
@ast
Phase I study of the humanised ...... in advanced pancreatic cancer.
@en
prefLabel
Phase I study of the humanised ...... in advanced pancreatic cancer.
@ast
Phase I study of the humanised ...... in advanced pancreatic cancer.
@en
P2093
P2860
P356
P1476
Phase I study of the humanised ...... in advanced pancreatic cancer.
@en
P2093
Th Südhoff
W Schmiegel
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603083
P407
P577
2006-05-01T00:00:00Z